It has been shown that DPP-4 inhibitor-treated type 2 diabetic patients had lower risks for cardiovascular disease as compared to those for non-DPP-4 inhibitor users, except metformin users [36], and its use did not increase the risk of heart failure compared with sulfonylurea [37]. Here, DPP4 is linked to cardiovascular disorder.